What frontline therapy would you offer for a patient who is elderly or unfit for standard induction therapy with both IDH-2 and FLT-3 ITD mutations?
Answer from: Medical Oncologist at Community Practice
For a newly diagnosed patient, unfit for induction chemotherapy with both an IDH2 and FLT3 mutation, I would offer HMA with venetoclax for the initial treatment. While both the IDH2 inhibitor Enasidenib and the FLT3 inhibitor Gilteritinib are both well-tolerated drugs with good remission rates, if y...
Sign in or Register to read more